The vaccine uses the same lipid nanoparticles (LNPs) as the Moderna COVID-19 vaccine. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA ...

Health Canada approves Moderna’s RSV vaccine, mRESVIA for adults aged 60 years and older: Cambridge, Massachusetts Monday, November 11, 2024, 12:00 Hrs [IST] Moderna, Inc., a le ...

GSK sued Moderna over the shots in Delaware federal court Tuesday, claiming the mRNA specialist ignored GSK-owned patents related to lipid mRNA vaccine formulation technology. The lawsuits ...

In this Thought Leader article., Ian Johnston from Cytiva discusses challenges related to process development, scaling technology, regulatory approvals, and GMP guidelines.

GSK claims Moderna used its patented mRNA vaccine ... These scientists developed formulations combining lipids and mRNA molecules to create vaccines that trigger immune responses against viral ...

This time, we have GSK (GSK) "GSK" filing a lawsuit against Moderna (NASDAQ:MRNA) accusing them of patent infringement on their lipid nanoparticle ... their COVID-19 vaccine, Spikevax, as well ...

Northwestern University has filed a patent infringement lawsuit against Moderna, Inc. MRNA ... s lipid nanoparticle (LNP) technology without permission to develop its COVID-19 vaccines.

A groundbreaking study introduces stable inhalable mRNA treatment using nanoparticles that hold up during nebulization, ...

Zylem Biosciences announced that Northwestern University has filed a lawsuit against Moderna (MRNA), alleging infringement of key patents related to mRNA vaccine technologies. The lawsuit ...

According to the two lawsuits, Moderna's lipid nanoparticles for transporting ... in 2008 that provides "the foundation for Moderna's mRNA vaccine portfolio." GSK said it bought the rights to ...

Oct 16 (Reuters) - Moderna (MRNA.O), opens new ... its blockbuster COVID-19 vaccine Spikevax. The lawsuit said, opens new tab Moderna uses Northwestern-developed lipid nanoparticle (LNP ...

mRNA-based innovator pharmaceuticals have experienced a massive increase in licensing agreement deal values following success with the technology in Covid-19 vaccines, which helped to curtail the ...